Modulated immunodominance therapy
AssigneeGeneius Biotechnology, Inc.
InventorAlfred E. SLANETZ
Life of this patent
Estimating the term…
Loading patent…
AssigneeGeneius Biotechnology, Inc.
InventorAlfred E. SLANETZ
Estimating the term…
The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting. In effect, the transplantation exogenously generated T cells reactive to the subdominant antigens is recapitulating priming and rebalancing the patient's immune response to target previously subdominant antigens in the cells or organism to produce a therapeutic benefit.
A T cell population capable of recognizing one or more subdominant antigens or epitopes in a patient for use in a method of altering the immunodominance hierarchy of the patient, the one or more subdominant antigens or epitopes comprising an antigen or an epitope to which a cellular or a humoral immune response is not detectable or is detectable at a low level in the patient.
-19. (canceled)
The T cell population of claim 29, wherein the viral antigen or epitope comprises a chronic viral antigen or a latent viral antigen.
A method of altering an immunodominance hierarchy in a patient, comprising administering a T cell population capable of recognizing one or more subdominant antigens or epitopes in the patient.
Dependencies are inferred from the claim text.